Combined therapy for cancer of the anal canal

Nigro, N; Vaitkevicius, Vainutis K.; Buroker, T.; Bradley, G.; Considine, Basil

doi:10.1007/bf02604287

Cited by 230 publications

(108 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Before 1980, APR was considered the standard treatment. The publishing of the results of the study by Nigro et al in 1981 elicited more interest in the combined-treatment approach, with concurrent chemoradiation 9. They reported on three patients with squamous cell carcinoma of the anal canal who after preoperative radiation with concurrent chemotherapy achieved complete remission of the primary tumor at the time of surgery.…”

Section: Discussionmentioning

confidence: 99%

Anal canal carcinoma treatment results: the experience of a single institution

El-Haddad

Ahmed

Al-Suhaibany

et al. 2011

Annals of Saudi Medicine

View full text Add to dashboard Cite

BACKGROUND AND OBJECTIVES:Prior to the mid-1980s, the treatment of choice for anal cancer was abdominoperineal resection. Currently, combined chemoradiation is the standard of care. Or objective was to analyze results of treatment for anal canal carcinoma treated with combined chemoradiation.DESIGN AND SETTING:0Retrospective review of data in local cancer registry at King Faisal Specialist Hospital and Research Centre (KFSHRC) from a 12-year period (1993 to 2005).METHODS:We identified patients with confirmed diagnosis of anal canal squamous cell carcinoma.RESULTS:Of 40 patients identified, 33 were considered eligible for our analysis. All patients were treated by concurrent chemoradiation with mandatory treatment break (MTB) There were 10 (30%) local recurrences. Five-year progression-free survival (PFS) was 50.9%; overall survival (OS) at 5 years was 73.4%. Patients with stage II disease had a median PFS period of 10 years, with no relapses until their last follow-up. There was no statistically significant difference in PFS between patients with stage IIIA disease and those with stage IIIB disease—44.7% and 45%, respectively (P=.8). Five-year PFS according to ‘T’ stages was as follows: T1, 66%; T2, 71%; T3, 59%; T4, 30% (P>.05). The 5-year colostomy-free survival (CFS) for all patients was 74%. Distant metastases were observed in 4 patients.CONCLUSION:Combined chemoradiation in treatment of anal cancer is effective in terms of local control and sphincter preservation. Five-year estimates of PFS, OS, as well as CFS, in patients treated with a MTB were surprisingly comparable to those determined in most non-MTB series. However, we reported a higher local failure rate, for which we are reevaluating our treatment protocol.

show abstract

Section: Discussionmentioning

confidence: 99%

Anal canal carcinoma treatment results: the experience of a single institution

El-Haddad

Ahmed

Al-Suhaibany

et al. 2011

Annals of Saudi Medicine

View full text Add to dashboard Cite

show abstract

“…6 Colorectal КОЛОПРОКТОЛОГИЯ 4' 2016 О р и г и н а л ь н ы е и с с л е д о в а н и я Введение В базовых принципах лечения плоскоклеточного рака анального канала произошли минимальные из-менения со времени внедрения N. D. Nigro и соавт. в 1974 г. схемы химиолучевой терапии (ХЛТ) с примене-нием 5-фторурацила и митомицина [1]. Было завершено только 6 рандомизированных исследований III фазы, показавшие, что ХЛТ превосходит лучевую терапию (ЛТ) [2,3], а сочетание 5-фторурацила с митомицином эффек-тивнее, чем монотерапия 5-фторурацилом [4], и индукци-онная химиотерапия и увеличение дозы буста ЛТ не при-водят к улучшению результатов лечения.…”

unclassified

The Use of Paclitaxel in Chemoradiotherapy of Patients With Squamous Cell Carcinoma of the Anal Canal: A Pilot Study

Гордеев¹,

Gorbunova²,

Ткачев³

et al. 2016

Onkol. koloproktol.

View full text Add to dashboard Cite

“…Esses apresentam mais metástases linfonodais, maiores taxas de recidiva, menor expectativa de vida, 11,12 e pior resposta à radio e quimioterapia associadas. 13 O tratamento do CEC anal, descrito por Nigro em 1974, 14 combina radio e quimioterapia. Operações de resgate estão indicadas caso haja persistência ou recidiva da doença.…”

unclassified

Seguimento dos doentes soropositivos e soronegativos para o HIV com carcinoma espinocelular do canal anal

Nadal

Cruz²

2009

Rev bras. colo-proctol.

View full text Add to dashboard Cite

RESUMO: A incidência do carcinoma espinocelular (CEC) anal e das neoplasias intra-epiteliais anais (NIA) é maior nos pacientes infectados pelo papilomavírus humano (HPV), e está relacionada à imunidade e à infecção pelo vírus da imunodeficiência humana (HIV). A associação com viroses de transmissão sexual indica que seja tumor sexualmente transmitido. A infecção pelo HIV mudou o perfil dos portadores do CEC anal. A doença que anteriormente acometia mulheres na 6 a década de vida, hoje atinge preferencialmente homens na 3ª e 4 a décadas. Nos Estados Unidos, a expectativa de diagnóstico desse tumor aumentou de 19/ 100.000, na época pré-HAART (1992-1995), para 48,3/100.000 no período pós-HAART imediato (1996-1999) e para 78,2/100.000 pessoas por ano, nos anos mais recentes (2000-2003). O tratamento do CEC anal, descrito por Nigro em 1974, combina radio e quimioterapia. Operações de resgate estão indicadas caso haja persistência ou recidiva da doença. Estudos comparando, respectivamente, doentes imunodeprimidos e imunocompetentes vêm mostrado envolvimento linfonodal em 60% e 17%, recidivas em 75% e 6%, boa resposta à radio e quimioterapia em 62% e 85%, toxicidade a esse tratamento em 80% e 30%, e sobrevivên-cia global de 1,4 e 5,3 anos. A contagem sérica baixa de linfócitos T CD4 prediz mau prognóstico. Quando acima de 200/mm 3 , os resultados são comparáveis aos observados entre os imunocompetentes.

show abstract

Combined therapy for cancer of the anal canal

Cited by 230 publications

References 7 publications

Anal canal carcinoma treatment results: the experience of a single institution

Anal canal carcinoma treatment results: the experience of a single institution

The Use of Paclitaxel in Chemoradiotherapy of Patients With Squamous Cell Carcinoma of the Anal Canal: A Pilot Study

Seguimento dos doentes soropositivos e soronegativos para o HIV com carcinoma espinocelular do canal anal

Contact Info

Product

Resources

About